Disease Domain | Count |
---|---|
Infectious Diseases | 3 |
Nervous System Diseases | 2 |
Neoplasms | 1 |
Immune System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Herbal medicine | 7 |
Small molecule drug | 1 |
Growth factors | 1 |
Top 5 Target | Count |
---|---|
FGFR2(Fibroblast growth factor receptor 2) | 1 |
Top I(DNA topoisomerase I) | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. China |
First Approval Date24 Nov 2021 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. China |
First Approval Date16 Dec 2019 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. China |
First Approval Date31 Mar 2009 |
Start Date10 Dec 2024 |
Sponsor / Collaborator |
Start Date17 Sep 2024 |
Sponsor / Collaborator |
Start Date30 Jul 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
TengHuangJianGu | Hyperostosis More | Approved |
Xiaoer Jingxing Zhike Granules | Acute Bronchitis More | Approved |
Yangxue Qufeng Zhitong Granule(Guangdong Fangsheng Jianmeng) | Headache More | NDA/BLA |
Fuyanle Capsule | Bacterial Vaginosis More | Phase 3 |
Jianwei Qutong pellets | Chronic nonatrophic gastritis More | Phase 3 |